Connect with us

Hi, what are you looking for?

Bnreport Business News Report

Politics

Destiny Pharma inks collaboration agreement with SporeGen for COVID-19 preventive nasal spray

Destiny Pharma PLC (LON:DEST) announced a collaboration agreement with UK biotech SporeGen to co-dev..

Destiny Pharma PLC (LON:DEST) announced a collaboration agreement with UK biotech SporeGen to co-develop SporeGen's SPOR-COV product as a novel, preventive treatment for COVID-19.

The pair received an £800,000 grant from Innovate UK to fund the majority of the £1mln preclinical programme.

Under the agreement, the parties will share any costs and commercial returns from SPOR-COV and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months.

Destiny Pharma will contribute with its expertise in pre-clinical and clinical drug development.

The SPOR‑COV product, already shown to provide complete protection in preclinical models of influenza virus, consists of a proprietary formulation of Bacillus bacteria that will be administered nasally as a spray.

The formulation is different to vaccines in that it utilises the innate immune system with the aim of developing COVID-19 protection a few days after dosing.

ARead More – Source
[contf]
[contfnew]

Proactiveinvestors

[contfnewc]
[contfnewc]

You May Also Like

Tech

Enlarge/ You wouldn't really want to use Nvidia's ..

Politics

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae.

Tech

Enlarge Oliver Morris/Getty Images) In response to an Ars re..

Finance

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

%d bloggers like this: